Document is current

Article History

Received: 7 May 2023

Revised: 10 July 2023

Accepted: 10 July 2023

First Online: 19 July 2023

Declarations

:

: Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan/Abbvie, Amgen, Angelini, Lilly, Lundbeck, Novartis, and Teva. Simona Guerzoni received honoraria and fees from Allergan/Abbvie, Lilly, Lundbeck, Teva, Novartis and Pfizer. Luigi Francesco Iannone received personal fees from Lilly and Teva and travel grants from Lundbeck. Carlo Baraldi received honoraria and fees from Allergan, Lilly, Lundbeck, Teva and Novartis. Renata Rao received honoraria for travel grants, honoraria for advisory boards, speaker panels from Novartis, Lillly, Teva, Allergan, Lundbeck. Francesca Schiano di Cola received speaker honoraria from Lilly, Lundbeck and Novartis. Sabina Cevoli received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, Amgen and Lundbeck. Raffaele Ornello reports speaker fees from Novartis and Lilly, travel grants from Teva, and support for publication from Novartis and Allergan. Carlo Lovati received grants from Novartis and Lilly. Maria Albanese has been a consultant and member of Advisory Board for Novartis, Teva, Lundbeck, Lilly, Allergan/Abbvie; has received funding for travel and speaker honoraria from Lusofarmaco, Angelini, Novartis, Lilly, Teva, Merck-Serono. Armando Perrotta received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Lilly, Novartis, and Teva. Ilaria Cetta reports personal fees from Lilly for speaker activities. Massimo Filippi is Editor-in-Chief of the Journal of Neurology and Associate Editor of Neurological Sciences, received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Pierangelo Geppetti received personal fees from Allergan, Lilly, Novartis, Amgen, TEVA; grants from Amgen, TEVA, Eli-Lilly, Allergan, Chiesi; Scientific Advisory Board, Endosome Therapeutics; Founding scientist of FloNext srl, Spinoff of the University of Florence. Simona Sacco reports personal fees from Allergan-AbbVie, AstraZeneca, Abbott, Teva, Novartis, Novo Nordisk, Medscape, Neurodiem and Eli Lilly. Claudia Altamura received travel grants and honoraria from Novartis, Lilly, Lusofarmaco, Laborest, Abbvie-Allergan, Almirall. Nicoletta Brunelli, Sergio Soeren Rossi and Valentina Taranta have nothing to disclose.

: The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from patients for collecting anonymously clinical and demographics data.